A majority of subjects in jaguar health's placebo-controlled pivotal phase 3 ontarget trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy chose to continue on to stage ii

Stage ii completed; comprehensive results expected in q1 2024; company's planned regulatory pathway for fda approval remains on track cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea san francisco, ca / accesswire / december 11, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) (jaguar) family company, today announced that a majority of subjects in the company's placebo-controlled pivotal phase 3 ontarget trial for prophylaxis (prevention) of diarrhea in adult cancer patients receiving targeted therapy with or without standard chemotherapy chose to continue on to stage ii of the two-stage trial. after completing the stage i double-blind, placebo-controlled primary prophylactic treatment phase of ontarget, subjects had the option to remain on their blinded assigned treatment arm and reconsent to enter into the stage ii extension phase.
JAGX Ratings Summary
JAGX Quant Ranking